Skip to content
10-Q

Quarterly Report

Aligos Therapeutics, Inc. ALGS

0001193125-26-212001

← back to feed
Filed
May 7, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted Q1 2026 · Mar 31, 2026 10.4M sh
Shares Diluted Q1 2026 · Mar 31, 2025 8.71M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$23.13M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$20.91M
Short Term Investments Q1 2026 · Mar 31, 2026 $24.93M
Short Term Investments Q1 2026 · Dec 31, 2025 $59.54M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $29.98M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $18.3M
Stockholders Equity Q1 2026 · Mar 31, 2026 $31.79M
Stockholders Equity Q1 2026 · Dec 31, 2025 $53.55M
Stockholders Equity Q1 2026 · Mar 31, 2025 $116.45M
Stockholders Equity Q1 2026 · Dec 31, 2024 −$28.97M
Current Liabilities Q1 2026 · Mar 31, 2026 $23.32M
Current Liabilities Q1 2026 · Dec 31, 2025 $21.23M
Total Liabilities Q1 2026 · Mar 31, 2026 $32.77M
Total Liabilities Q1 2026 · Dec 31, 2025 $34.99M
Current Assets Q1 2026 · Mar 31, 2026 $59.63M
Current Assets Q1 2026 · Dec 31, 2025 $82.86M
Total Assets Q1 2026 · Mar 31, 2026 $64.56M
Total Assets Q1 2026 · Dec 31, 2025 $88.53M
Eps Diluted Q1 2026 · Mar 31, 2026 −$2.21
Eps Diluted Q1 2026 · Mar 31, 2025 −$2.11
Eps Basic Q1 2026 · Mar 31, 2026 −$2.21
Eps Basic Q1 2026 · Mar 31, 2025 $5.12
Sga Expense Q1 2026 · Mar 31, 2026 $6.41M
Sga Expense Q1 2026 · Mar 31, 2025 $5.05M
Rd Expense Q1 2026 · Mar 31, 2026 $23.35M
Rd Expense Q1 2026 · Mar 31, 2025 $14.5M
Net Income Q1 2026 · Mar 31, 2026 −$23.04M
Net Income Q1 2026 · Mar 31, 2025 $43.09M
Operating Income Q1 2026 · Mar 31, 2026 −$26.93M
Operating Income Q1 2026 · Mar 31, 2025 −$19.24M
Revenue Q1 2026 · Mar 31, 2026 $2.83M
Revenue Q1 2026 · Mar 31, 2025 $311K